REPORTING OF CARDIOVASCULAR EVENTS IN CLINICAL TRIALS SUPPORTING FDA-APPROVAL OF CONTEMPORARY CANCER DRUGS

被引：1
|
作者：
Addison, Daniel [1 ]
Bonsu, Janice [1 ]
Charles, Lawrence [1 ]
Guha, Avirup [1 ]
Baker, Brandee [1 ]
Woyach, Jennifer [1 ]
Awan, Farrukh [1 ]
Rogers, Kerry [1 ]
Lustberg, Maryam [1 ]
Reinbolt, Raquel [1 ]
Brammer, Jonathan [1 ]
Miller, Eric [1 ]
Jneid, Hani [1 ]
Paskett, Electra [1 ]
机构：
[1] Ohio State Univ, Columbus, OH 43210 USA
来源：
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY | 2019年 / 73卷 / 09期
关键词：
D O I：
10.1016/S0735-1097(19)32485-4
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1331-429
引用
收藏
页码：1879 / 1879
页数：1
相关论文
共 50 条
  • [41] Systematic review of a personalized strategy in cancer clinical trials leading to FDA approval.
    Jardim, Denis Leonardo Fontes
    Schwaederle, Maria Clemence
    Lee, J. Jack
    Hong, David S.
    Eggermont, Alexander M.
    Schilsky, Richard L.
    Mendelsohn, John
    Lazar, Vladimir
    Kurzrock, Razelle
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [42] Registration, publication, and outcome reporting among pivotal clinical trials that supported FDA approval of high-risk cardiovascular devices before and after FDAAA
    Matthew J. Swanson
    James L. Johnston
    Joseph S. Ross
    Trials, 22
  • [43] Registration, publication, and outcome reporting among pivotal clinical trials that supported FDA approval of high-risk cardiovascular devices before and after FDAAA
    Swanson, Matthew J.
    Johnston, James L.
    Ross, Joseph S.
    TRIALS, 2021, 22 (01)
  • [44] Fragility index of trials supporting approval of anti-cancer drugs in common solid tumours
    Desnoyers, Alexandra
    Wilson, Brooke E.
    Nadler, Michelle B.
    Amir, Eitan
    CANCER TREATMENT REVIEWS, 2021, 94
  • [45] Human radiolabeled mass balance studies supporting the FDA approval of new drugs
    Ramamoorthy, Anuradha
    Bende, Girish
    Chow, Edwin Chiu Yuen
    Dimova, Hristina
    Hartman, Neil
    Jean, Daphney
    Pahwa, Sonia
    Ren, Yunzhao
    Shukla, Chinmay
    Yang, Yuching
    Doddapaneni, Suresh
    Danielsen, Zhixia Yan
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2022, 15 (11): : 2567 - 2575
  • [46] Feasibility of Emulating Clinical Trials Supporting US FDA Supplemental Indication Approvals of Drugs and Biologics
    Janda, Guneet S.
    Wallach, Joshua D.
    Dhodapkar, Meera M.
    Ramachandran, Reshma
    Ross, Joseph S.
    JAMA INTERNAL MEDICINE, 2023, 183 (11) : 1271 - 1273
  • [47] Characteristics of Clinical Trials to Support Approval of Orphan vs Nonorphan Drugs for Cancer
    Kesselheim, Aaron S.
    Myers, Jessica A.
    Avorn, Jerry
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2011, 305 (22): : 2320 - 2326
  • [48] Breast cancer drugs: FDA approval, development time, efficacy, clinical benefits, innovation, trials, endpoints, quality of life, value, and price
    Michaeli, Julia Caroline
    Michaeli, Thomas
    Trapani, Dario
    Albers, Sebastian
    Dannehl, Dominik
    Wuerstlein, Rachel
    Michaeli, Daniel Tobias
    BREAST CANCER, 2024, 31 (06) : 1144 - 1155
  • [49] US FDA streamlines safety reporting in clinical trials
    Reactions Weekly, 2011, 1356 (1) : 2 - 2
  • [50] Racial and ethnic enrollment disparities in clinical trials leading to FDA approval of gynecologic cancer treatment
    Scalia, Peter
    Gilbert, Lucy
    Bernard, Laurence
    Zeng, Xing
    Franco, Luis Pareja
    Levin, Gabriel
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2024, 34 (SUPPL_3) : A83 - A83
12345